MannKind Corp

MNKD remains range-bound under its descending 200-day SMA between support at 3.90–3.95 and resistance at 4.15–4.20. The medium-term bias is Bullish, reflecting a Stage 2 consolidation with a rounded base, but short-term EMAs are flat and momentum is neutral, offering no immediate timing edge. Execution should be deferred, waiting for either a pullback into the converged 9/20/50 EMA zone near support or a decisive breakout above the 200-day SMA. Structurally, the long-term trend remains Bearish until price can reclaim and hold above the 200-day SMA, which poses the primary risk to this view.

• ↑Revenue +43% YoY in Q2 to $109.4M; H1 +29% to $199.5M
• ↑Afrezza pediatric launch sees one-third of top 100 prescribers adopting
• ↓Net loss $19M in Q2 vs $0.7M income YoY highlights weak profitability